Center Of Excellence Not Best Model For US FDA Rare Disease Program, Woodcock Says
Executive Summary
Center for Drug Evaluation and Research Director says rare disease reviews need multiple specialists, which likely would not fit into a centralized rare disease review group.
You may also be interested in...
US FDA's CDER Creates Quantitative Medicine Center Of Excellence; Job Includes AI Oversight
The group will coordinate quantitative medicine issues throughout the FDA's Center for Drug Evaluation and Research to help streamline drug development.
New US FDA Genetic Metabolic Adcomm Needs More Candidates
Given the enthusiasm for the new advisory committee within the rare disease community, the need for an extended deadline is somewhat surprising. FDA has not yet determined when the chair and members of the new panel will be named.
Genetic Metabolic Diseases Get Their Own US FDA Advisory Committee
In a first for rare diseases, a new standing committee will provide advice and recommendations on technical, scientific and policy issues related to medical products for genetic metabolic diseases.